期刊文献+

美国多中心临床试验伦理审查经验对我国的启示——以美国国家癌症研究院为例 被引量:10

Enlightenment of Ethical Review Experience of Multi-Center Clinical Trials in the United States to Our Country:Taking the National Cancer Institute of the United States as an Example
下载PDF
导出
摘要 随着生物医学的不断发展,多中心临床合作日益增多,多中心伦理审查成为国际趋势。我国多中心伦理审查起步较晚,理论和实践方面仍存在问题。通过检索美国多中心伦理审查的相关文献,以美国国家癌症研究院为例介绍美国伦理审查的研究经验,并进行本土化研究。提出完善我国多中心临床试验的法律及指南,确立一元制的审查模式,设置不同类型中心伦理委员会,建立组长单位中心审查网站四个方面建议,以逐步完善我国多中心伦理审查工作。 With the development of biomedical science, muhi -center clinical cooperation is increasing, and muhi - center ethical review has become an international trend. China' s muhi - center ethical review started late, and there are still problems in the theory and practice. Through the retrieval of relevant literature about muhi - cen- ter ethical review in the United States, taking the National Cancer Institute (NCI) as an example, this paper intro- duced the research experience of American ethical review and carried out localization research. In order to gradual- ly consummate the muhi - center ethical review work of our country, this paper put forward four suggestions of con- summating the laws and guidelines, establishing the examination mode of the centralized leadership system, setting up dirt)rent types of central ethics committee and establishing the unit center review website .
作者 管宇萌 张雪 马佳乐 GUAN Yumeng;ZHANG Xue;MA Jiale(School of Humanities and Social Sciences,Harbin Medical University,Harbin 150081,China)
出处 《中国医学伦理学》 2018年第8期1052-1055,共4页 Chinese Medical Ethics
基金 南京医科大学人文协同创新中心课题:伦理审查委员会跟踪审查制度本土化研究(JX21831802/006/006)
关键词 多中心临床试验 伦理审查 伦理委员会 Multi -Center Clinical Trial Ethical Review Ethics Committee
  • 相关文献

参考文献2

二级参考文献20

  • 1Goh BC.Design of phase I and II clinical trials in on- cology and ethical issues involved[J].Ann Acad Med Sin- gapore,2000,29(5):588-597.
  • 2Rothenberger LG,Henschel AD,Schrey D,et al.Method- ological and ethical aspects of randomized controlled clini- cal trials in minors with malignant diseases[J].Pediatr Blood Cancer,2012;59(1):205.
  • 3Daugherty CK,Siegler M,Ratain MJ,et al.Learning from our patients:one participant's impact on clinical trial re- search and informed consent[J].Ann Intern Med,1997,126(11):892-897.
  • 4Daugherty CK.Ethical issues in the development of new agents[J].Invest New Drugs,1999,17(2):145-153.
  • 5Riechelmann RP,Wang L,O'Carroll A,et al.Disclosure of conflicts of interest by authors of clinical trials and editori- als in oncology[J].J Clin Oncol,2007,25(29):4642-4647.
  • 6Agulnik M,Oza AM,Pond GR,et al.Impact and percep- tions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents[J].J Clin On- col,2006,24(30):4801-4807.
  • 7Deng C,Hanna K,Bril V,et al.Challenges of clinical trial design when there is lack of clinical equipoise:use of a response-conditional crossover design[J].J Neurol,2012,259(2):348-352.
  • 8Beskow LM,Namey EE,Cadigan RJ,et al.Research par- ticipants,perspectives on genotype-driven research recruit- ment[J].J Empir Res Hum Res Ethics,2011,6(4):3-20.
  • 9Gupta P,Gupta V,Gupta YK.Phase I clinical trials of anticancer drugs in healthy volunteers:need for critical consideration[J].Indian J Pharmacol,2012,44(4):540-542.
  • 10Forster MD,Saijo N,Seymour L,et al.Performing phase I clinical trials of anticancer agents:perspectives from within the European union and Japan[J].Clin Cancer Res,2010,16(6):1737-1744.

共引文献12

同被引文献67

引证文献10

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部